Below are current clinical trials.103 studies in Breast Clinic
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to evaluate the efficacy of a new Mayo Clinic intervention in which preventive cardiology practitioners provide a baseline assessment of the nutritional and functional status and comorbidities of cancer survivors and then develop an individualized, independent exercise program.
Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The primary purposes of this study are to evaluate the safety and tolerability of VE800 in combination with Nivolumab in terms of adverse event (AE) rates using Common Terminology Criteria for Adverse Events (CTCAE, v. 5.0), and to evaluate clinical activity as measured by objective response rate (ORR) of the study drug combination using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.
The purpose of this trial is to evaluate the safety of GEN1046 in patients with malignant solid tumors.
La Crosse, Wis., Eau Claire, Wis., Rochester, Minn., Albert Lea, Minn., Austin, Minn.
The purpose of this study is to analyze the prevalence of mood disorders in newly-diagnosed breast cancer patients with use of specific questionnaires, aimed to diagnose clinically significant depression and anxiety, at a rural community hospital.
Mankato, Minn., Rochester, Minn., La Crosse, Wis., Eau Claire, Wis., Jacksonville, Fla., Albert Lea, Minn.
This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
Jacksonville, Fla., Rochester, Minn.
The purpose of this study is to determine the safety, effcicacy and tolerability of H2NVAC in patients with HER2-expressing DCIS in order to prevent future invasive breast cancer among patients who are diagnosed with DCIS.
Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
This phase II trial studies how well FASN inhibitor TVB-2640 and trastuzumab plus either paclitaxel or endocrine therapy with an aromatase inhibitor work in treating patients with HER2 positive breast cancer that has spread to other places in the body. FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and trastuzumab, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Endcocrine therapy helps reduce the hormones that feed tumor cells. Giving FASN inhibitor TVB-2640 and trastuzumab with either paclitaxel or endocrine therapy may work better in treating patients with HER2 positive breast cancer.
The purpose of this study is to assess the safety of in vivo in host drug sensitivity testing in patients with breast cancer and patients with lymphoma (nodal, extranodal masses, or cutaneous lesions).
Rochester, Minn., Scottsdale/Phoenix, Ariz.
The purpose of this study is to determine the safety, tolerability, activity, and drug/body interactions of Oradoxel for the treatment of patients who have advanced malignancies.
Rochester, Minn., Jacksonville, Fla.
The primary objective of this study is to compare progression-free survival (PFS) in patients with advanced HER2-positive breast cancer treated with T-DM1 and abemaciclib vs. T-DM1 monotherapy.
April 23, 2021